Cite
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
MLA
de Castro Baccarin, Ana Luísa, et al. “The Feasibility of Dexamethasone Omission in Weekly Paclitaxel Treatment for Breast Cancer Patients.” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, vol. 27, no. 3, Mar. 2019, pp. 927–31. EBSCOhost, https://doi.org/10.1007/s00520-018-4381-0.
APA
de Castro Baccarin, A. L., Irene, M. N., de Iracema Gomes Cubero, D., Luz, A. S., Castro, S. N., Sordi, R., Móz, L. E. S., & Del Giglio, A. (2019). The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 27(3), 927–931. https://doi.org/10.1007/s00520-018-4381-0
Chicago
de Castro Baccarin, Ana Luísa, Macilon Nonato Irene, Daniel de Iracema Gomes Cubero, Ariana Sales Luz, Suelen Nastri Castro, Renan Sordi, Luis Eduardo Silva Móz, and Auro Del Giglio. 2019. “The Feasibility of Dexamethasone Omission in Weekly Paclitaxel Treatment for Breast Cancer Patients.” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 27 (3): 927–31. doi:10.1007/s00520-018-4381-0.